Abstract
(Am J Obstet Gynecol. 2022;226:510–523.e22) Postpartum hemorrhage (PPH) affects 1% to 10% of pregnancies worldwide and is associated with high maternal morbidity and mortality rates. Early diagnosis, prophylactic oxytocin, and prompt treatment is the recommended strategy for reducing blood loss during PPH. Tranexamic acid (TXA) may reduce the risk of death in patients with PPH. While previous meta-analyses on the use of prophylactic TXA during cesarean delivery have only used small sample sizes, the recent Tranexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery (TRAAP2) trial is adequately powered and examined long-term risks of prophylactic TXA alongside the benefits. This meta-analysis aimed to compare prophylactic TXA with standard uterotonic agents alone in terms of efficacy and safety in patients having a cesarean delivery.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
